GRAFAPEX helped more patients achieve overall survival1

GRAFAPEX was evaluated in a randomized active-controlled trial versus busulfan in combination with fludarabine as a preparative regimen for allogeneic transplantation1

icon-people
Adults aged 18 to 70 years old with AML or MDS
icon-gauge
Karnofsky Performance Status ≥60%
icon-stem-cell
Age ≥50 years or HCT-CI score >2 or both

Kaplan-Meier estimates of OS since time of randomization

Kaplan-Meier chart showing the rate of overall survival since time of randomization for patients on busulfan vs treosulfan.
Event-free survival and non-relapse mortality were studied as part of the trial design.2

 For more information on the efficacy, safety, and dosing of GRAFAPEX, download our GRAFAPEX Product Overview

Efficacy was established based on OS, which was defined as the time from randomization until death from any cause1

The HR for OS compared to busulfan was:

0.67

(95% CI: 0.51, 0.90) 
in the randomized population

0.73

(95% CI: 0.51, 1.06) 
in patients with AML

0.64

(95% CI: 0.40, 1.02)
in patients with MDS

To learn more about the efficacy of GRAFAPEX, download the full Prescribing Information

AML, acute myeloid leukemia; CI, confidence interval; HCT-CI, hematopoietic cell transplantation comorbidity index; HR, hazard ratio; MDS, myelodysplastic syndrome; OS, overall survival.